The company said its Board of Directors declared a cash dividend of $0.72 per share of common stock on January 8, 2025.

8-KRegulation FD DisclosureFiled Jan 10, 2025Period of report Jan 8, 2025Summary published (UTC) Oct 17, 2026

Key points

AI summary

The company said its Board of Directors declared a cash dividend of $0.72 per share of common stock on January 8, 2025.
The company said the dividend will be paid on March 12, 2025 to stockholders of record as of the close of business on February 27, 2025.
The company said it disclosed the dividend declaration under Item 7.01 (Regulation FD Disclosure) and furnished the January 8, 2025 press release as Exhibit 99.1.
In the press release, the company said it serves clients through more than 67,000 employees in approximately 100 countries, supported 84% of the new drugs and therapeutic products approved by the FDA in 2023, and performed more than 600 million tests.

Summary

AI-written

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

Labcorp Declares $0.72 Cash Dividend per Share

The company said its Board of Directors declared a cash dividend of $0.72 per share of common stock on January 8, 2025.

Source · Based on the filing body and exhibits

Dividend Payment and Record Dates

The company said the dividend will be paid on March 12, 2025 to stockholders of record as of the close of business on February 27, 2025.

Source · Based on the filing body and exhibits

Reg FD Disclosure and Press Release Attached

The company said it disclosed the dividend declaration under Item 7.01 (Regulation FD Disclosure) and furnished the January 8, 2025 press release as Exhibit 99.1.

Source · Based on the filing body and exhibits

Labcorp Company Overview

In the press release, the company said it serves clients through more than 67,000 employees in approximately 100 countries, supported 84% of the new drugs and therapeutic products approved by the FDA in 2023, and performed more than 600 million tests.

Source · Based on the filing body and exhibits

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.

View the original filing on SEC EDGAR ↗

Unauthorized scraping, data storage and database creation prohibited

Without prior written consent, you must not crawl or scrape data compiled and organized by Chickstock or its analysis and summaries, or collect them repeatedly or in bulk for storage, ingestion or database creation. Repurposing, redistribution, sale and use to build other services are also prohibited.

Unauthorized use may result in access restrictions, demands to stop infringement and delete copies, and claims for damages. Violations of applicable law may also give rise to criminal liability.

Uses permitted by law, the Terms of Service or a separate agreement remain subject to their respective scope. Rights in individual source materials, including original filings, remain with their respective rights holders.